Duvelisib with docetaxel for patients with anti-PD-1 refractory, recurrent or metastatic head and neck squamous cell carcinoma.
Hanna GJ, Oakley LB, Shi R, ONeill A, Shin KY, Scarfo N, Sehgal K, Dennis MJ, Quinn N, Jo VY, Wong K, Shvyrkova A, Kushnarev V, Shanthappa BU, Tkachuk A, Kryukov K, Sarachakov A, Svekolkin V, Lennerz J, Waters S, Haddad RI.
Hanna GJ, et al. Among authors: wong k.
Clin Cancer Res. 2024 Dec 3. doi: 10.1158/1078-0432.CCR-24-2262. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 39625478